1. Clinical & Scientific Overview
Mesna (Sodium 2-Mercaptoethanesulfonate) (TIP-MED-000579, Reference Code [ONC-30]) is classified under
Oncology & Antineoplastic Medicines as a Oncology Supportive Care (Uroprotector) • Sulfhydryl Uroprotective Cytoprotectant for Oxazaphosphorine Chemotherapy.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Uromitexan (Baxter Oncology), Mesna-Z (Zydus Oncology), Biomesna (Biochem)
Solution for IV Injection: 100 mg/mL (2 mL = 200 mg and 4 mL = 400 mg ampoules)
Oncology Specialisation & Cytotoxic Safety Protocol
Oncology Supportive Care (Uroprotector)
Oncology Supportive Care / Cytoprotective Adjunct (Not Direct Antineoplastic)
Standard Regimen & Cycle Context: Standard IV Bolus Protocol: 20% w/w of the Ifosfamide dose given IV at 0 hours (with ifosfamide), 4 hours, and 8 hours (total 60% of ifosfamide dose), or continuous IV infusion.
Signature Dose-Limiting Toxicities & Organ Monitoring: Explicitly classified as an Oncology Supportive-Care Cytoprotective Agent (not an antineoplastic); does NOT prevent ifosfamide nephrotoxicity or encephalopathy; causes false-positive urinary ketone test results on nitroprusside dipsticks and unpleasant sulfur taste if given orally.
Extravasation, Premedication & Safe Cytotoxic Handling: Maintain concurrent forced IV hydration (2–3 L/day) alongside Mesna to ensure brisk urine output (>100 mL/hr) and check morning urine dipstick for erythrocytes prior to each oxazaphosphorine dose.
3. Mechanism of Action & Pharmacodynamics
In plasma, Mesna is rapidly oxidised to inactive dimesna (so it does NOT reduce the systemic antitumour activity of ifosfamide/cyclophosphamide); after glomerular filtration, renal tubular glutathione reductase reduces dimesna back to active free-thiol Mesna in the urine, where it binds and detoxifies urotoxic acrolein and 4-hydroxy metabolites in the bladder.
4. Therapeutic Indications & Evidence-Supported Uses
- Prevention of ifosfamide-induced and high-dose cyclophosphamide-induced haemorrhagic cystitis
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): Standard IV Bolus Protocol: 20% w/w of the Ifosfamide dose given IV at 0 hours (with ifosfamide), 4 hours, and 8 hours (total 60% of ifosfamide dose), or continuous IV infusion.
Administration & Meal Timing: Standard IV Bolus Protocol: 20% w/w of the Ifosfamide dose given IV at 0 hours (with ifosfamide), 4 hours, and 8 hours (total 60% of ifosfamide dose), or continuous IV infusion.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Mesna or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: Explicitly classified as an Oncology Supportive-Care Cytoprotective Agent (not an antineoplastic); does NOT prevent ifosfamide nephrotoxicity or encephalopathy; causes false-positive urinary ketone test results on nitroprusside dipsticks and unpleasant sulfur taste if given orally.
8. Adverse Effects Profile
- Explicitly classified as an Oncology Supportive-Care Cytoprotective Agent (not an antineoplastic); does NOT prevent ifosfamide nephrotoxicity or encephalopathy; causes false-positive urinary ketone test results on nitroprusside dipsticks and unpleasant sulfur taste if given orally.
- Explicitly classified as an Oncology Supportive-Care Cytoprotective Agent (not an antineoplastic); does NOT prevent ifosfamide nephrotoxicity or encephalopathy; causes false-positive urinary ketone test results on nitroprusside dipsticks and unpleasant sulfur taste if given orally.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Explicitly classified as an Oncology Supportive-Care Cytoprotective Agent (not an antineoplastic); does NOT prevent ifosfamide nephrotoxicity or encephalopathy; causes false-positive urinary ketone test results on nitroprusside dipsticks and unpleasant sulfur taste if given orally.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Maintain concurrent forced IV hydration (2–3 L/day) alongside Mesna to ensure brisk urine output (>100 mL/hr) and check morning urine dipstick for erythrocytes prior to each oxazaphosphorine dose.
Pharmacist Patient Counselling Points:
- Maintain concurrent forced IV hydration (2–3 L/day) alongside Mesna to ensure brisk urine output (>100 mL/hr) and check morning urine dipstick for erythrocytes prior to each oxazaphosphorine dose.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Maintain concurrent forced IV hydration (2–3 L/day) alongside Mesna to ensure brisk urine output (>100 mL/hr) and check morning urine dipstick for erythrocytes prior to each oxazaphosphorine dose.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.